Adeshakin AO; Shi H; Perry SS; Sheppard H; Nguyen P; Sun X; Zhou P; Métais JY; Cunningham T; Kc A; Tian L; Peche V; Prater MS; Langfitt DM; O'Reilly C; Park JJ; Chabot A; Zhou S; Matsubara A; Lee G; Tsai SQ; Pruett-Miller SM; Talbot LJ; Yustein JT; Krenciute G; DeRenzo C; Chi H; Gottschalk S · 2026 · Cell reports. Medicine
Paper
The microenvironment in solid tumors represents an immunosuppressive therapeutic barrier to CAR T cell therapy, and it is currently unknown whether it can be reshaped by the deletion of negative regulators in CAR T cells. To address this knowledge gap, we evaluated the intrinsic and extrinsic effects of deleting the negative regulator Regnase-1 (Reg-1) in B7-H3-CAR T cells for the immunotherapy of osteosarcoma. Reg-1 knockout (KO) improved the antitumor activity of human and murine B7-H3-CAR T cells in vivo. In immune-competent models, Reg-1 KO also endowed murine B7-H3-CAR T cells with the ability to create a proinflammatory landscape characterized by an influx of interferon gamma (IFN-γ)-producing endogenous T cells and natural killer (NK) cells and a reduction of inhibitory myeloid cells, including M2-like macrophages. Thus, deleting Reg-1 has cell- and non-cell-autonomous benefits, nominating Reg-1 KO B7-H3-CAR T cells as a promising cell product for early-phase clinical testing in patients with solid tumors.
Analysis
Preparing paper insights from the available abstract and paper details.
Discovery
Xudong Wang; Jin Zhang
Su FI
Shin JH; Song Y; Park J
Huang J; Wang Q; Yao Z; Wang Q; Ji Y; Yang M; Wang M; Shao S; Zhao X; Zhang F; Liang T; Hu Q
Li Y; Zhang X; Chen Y; Lin J; Liang T; Bai X
Xia T; Wei C; Chen X
Source record